A share price of Anixa Biosciences Inc [ANIX] is currently trading at $3.40, up 23.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The ANIX shares have gain 17.65% over the last week, with a monthly amount glided 29.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Anixa Biosciences Inc [NASDAQ: ANIX] stock has seen the most recent analyst activity on March 21, 2025, when Maxim Group initiated its Buy rating and assigned the stock a price target of $10. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 23, 2022, and set its price target to $8. On April 12, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $11 on the stock.
Anixa Biosciences Inc experienced fluctuations in its stock price throughout the past year between $2.07 and $4.20. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Anixa Biosciences Inc [NASDAQ: ANIX] shares were valued at $3.40 at the most recent close of the market. An investor can expect a potential return of 194.12% based on the average ANIX price forecast.
Analyzing the ANIX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.6 and Total Capital is -0.8. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.21 points at the first support level, and at 3.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.59, and for the 2nd resistance point, it is at 3.77.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Anixa Biosciences Inc [NASDAQ:ANIX] is 8.89. On the other hand, the Quick Ratio is 8.89, and the Cash Ratio is 0.53.
Transactions by insiders
Recent insider trading involved KUMAR AMIT, Chief Executive Officer, that happened on Jun 04 ’25 when 10000.0 shares were purchased. Director, Baskies Arnold M completed a deal on Jan 28 ’25 to buy 5000.0 shares. Meanwhile, Director Titterton Lewis H jr bought 2000.0 shares on Jan 23 ’25.
